Loading…
Loading…
The moves that matter — curated from across forex, stocks and crypto, and readable in full right here.
Updated 1 Oct, 01:30 am
Analyst sentiment on Tesla (NASDAQ: TSLA) remains divided, with bullish firms focused on autonomy, Semi production, and energy storage, while more cautious firms point to delivery and valuation risks. Cantor Fitzgerald reiterated an “ Overweight ” rating and a $485.00
A director of Espey Manufacturing and Electronics Corp sold 100 shares of common stock at $64.49 per share. Despite strong financial health, the stock is considered significantly overvalued at 111.9% above its estimated fair value. The insider transaction occurred after the relea
Vail Resorts, Inc. (NYSE: MTN) reported Q4 earnings per share (EPS) of -$5.34 , slightly exceeding analyst consensus. The company's total revenue reached $278.10 million , surpassing estimates. Vail Resorts is targeting $106 million in annualized operational efficiencies to enhan
Revenue Decline Expected : Analysts project a 1.4% decrease in quarterly revenues to approximately $2.59 billion , driven by soft consumer spending and inflation. EPS Drop and Dividend Cut: Earnings per share (EPS) are forecast to fall by 20.5% to around $0.31 , following a recen
An analyst from Morgan Stanley set a new price target of $295.00 for Reinsurance Group of America, suggesting a potential increase of approximately 16.67% from its trading price of $252.85 . Reinsurance Group of America's Financial Solutions adjusted operating income saw a signif
Analyst firm H.C. Wainwright raised its price target for Mirum Pharmaceuticals to $195.00 from $140.00, indicating strong confidence in the biopharmaceutical company's future. The company's drug Brelovitug met its main goal in the Phase 3 AZURE-1 study for Chronic Hepatitis Delta
Kodiak Sciences' lead drug candidates, Zenkuda and tabirafusp-ted, achieved primary goals in the Phase 3 DAYBREAK study for wet age-related macular degeneration (wAMD), demonstrating vision gains comparable to Regeneron's Eylea. Zenkuda showed strong efficacy, allowing 54% of pat
Citigroup has maintained a Neutral rating on Regeneron Pharmaceuticals , citing increasing competition in the ophthalmology sector . Positive Phase 3 trial results from Kodiak Sciences for its eye drugs present a significant challenge to Regeneron's key product, Eylea. Despite co
Vertex Pharmaceuticals maintains a dominant position in the cystic fibrosis market, driving consistent revenue growth and strong financial performance. Analyst firm UBS has raised its price target for Vertex Pharmaceuticals , reflecting confidence in the company's current perform
Strong AI-driven Growth: Accenture (NYSE: ACN) is experiencing significant growth, with its stock surging 37.6% due to increasing demand for artificial intelligence (AI) and the launch of new AI-focused services, outpacing industry growth. Positive Analyst Outlook: An analyst at
Space Exploration Technologies Corp. (NASDAQ: SPCX) , commonly known as SpaceX, remains in focus as Starship prepares for its first orbital mission and its first operational Starlink V3 satellite deployment. Analyst coverage remains broadly positive, with investor optimism tied t
Argus Research initiated coverage on 10x Genomics (NASDAQ: TXG) with a "Buy" rating and a price target of $110.00 , suggesting a potential 28.34% upside from its trading price of $85.71 . The stock demonstrates positive momentum, trading above its 50-day moving average of $60.74
Morgan Stanley reiterated an "Overweight" rating for Cullen/Frost Bankers, Inc. (NYSE: CFR), raising its price target to $201.00 . Several major institutional investors, including State Street Corp and BlackRock Inc., have significantly increased their holdings or initiated new p
Strong Earnings Growth Anticipated: Analysts project significant increases in earnings per share (EPS) and revenue for AAR Corp.'s upcoming quarterly report compared to the previous year. Positive Profitability Outlook: The company expects healthy EBITDA margins (between 12.25% a
Royal Caribbean Cruises Ltd. (NYSE:RCL) is strategically expanding its travel and leisure platform by acquiring a 50% stake in Sandals and Beaches Resorts, entering the all-inclusive resort sector . Analysts show strong confidence, with Bank of America Securities upgrading Royal
CarMax, Inc. (NYSE: KMX) is set to announce its Q3 earnings on September 29, 2026, with analysts forecasting an EPS of around $0.73 and revenue of approximately $7.09 billion . Despite a soft auto market, CarMax anticipates an increase in revenue compared to the previous year, th
Micron Technology (NASDAQ: MU) is a key player in the AI boom , with analysts setting a high price target and anticipating substantial earnings growth . Strong AI-driven demand for memory and storage , including DRAM , NAND , and HBM4 , is fueling Micron's projected earnings surg
Analyst firm Piper Sandler raised its price target for Capital One (NYSE: COF) to $260.00 from $254.00, maintaining an Overweight rating, signaling a strong outlook for the financial services stock. CEO Richard Fairbank highlights resilient consumer strength, with robust credit p
Headlines provided by Investing.com